Rethinking a lifetime of managing Type 1 Diabetes.
Type 1 Diabetes
KRIYA.288 is a one-time investigational gene therapy for type 1 diabetes, designed to improve glucose control independent of pancreatic function following a one-time intramuscular administration procedure.
Patients with type 1 diabetes are not able to make insulin, leading to dysregulation of blood glucose levels. Despite significant advances in insulin formulation and delivery, 70 to 80% of people with type 1 diabetes have blood glucose levels that exceed the American Diabetes Association’s recommended targets. As a result, many patients are at risk of developing long-term complications, including blindness, cardiovascular disease, and kidney failure.
KRIYA.288
How it works
In type 1 diabetes, the body loses the cells that sense glucose and produce insulin, leaving blood sugar without its natural control mechanism. In its place comes the burden of constant management, monitoring, calculating, and insulin dosing around the clock, day in and day out.
Glucokinase acts as a glucose-sensing enzyme: when blood glucose rises, glucokinase enhances glucose uptake and metabolism inside cells, thereby reducing glucose levels in the blood. KRIYA.288 is designed to express glucokinase in skeletal muscle cells following a one-time administration, so muscles can help metabolize excess glucose in a glucose-responsive way.
Loading…
Failed to load vial.
KRIYA.288 Specifications
| Indication | Type 1 diabetes |
|---|---|
| Modality | AAV-based gene therapy |
| Mechanism | Glucose-responsive glucose clearance |
| Payload | Glucokinase |
| Delivery | Intramuscular, outpatient |
| Dosing frequency | One-time administration |
| Potential patient impact | ~5 million, US and EU |
| Stage | Phase 1/2 |
Disclaimer
Kriya’s durable medicines are investigational and have not been approved as safe or effective by any regulatory health authority.
